What impact has COVID-19 had on HTA bodies and Pharma Pricing and Market Access activities?

HTA bodies and companies within the pharmaceutical industry have been forced to react to unprecedented levels of disruption due to COVID-19. A survey of employees within pricing and market access in pharma and biotech companies together with analysis of HTA decision-making in Europe was conducted to ascertain the impact the pandemic has had on the pharmaceutical industry.